{"denoms":[{"counts":[{"groupId":"BG000","value":"411"},{"groupId":"BG001","value":"409"},{"groupId":"BG002","value":"820"}],"units":"Participants"}],"groups":[{"description":"Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal\n\nChemotherapy: As prescribed","id":"BG000","title":"Chemotherapy"},{"description":"Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal\n\nChemotherapy: As prescribed\n\nBevacizumab: Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.","id":"BG001","title":"Chemotherapy + Bevacizumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.55","value":"61.9"},{"groupId":"BG001","spread":"9.78","value":"62.1"},{"groupId":"BG002","spread":"9.66","value":"62.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"294"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"259"},{"groupId":"BG001","value":"267"},{"groupId":"BG002","value":"526"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}